SubsidieMeestersIntracellular Carrier Against Resistant microOrganisms (ICARO)
The ICARO project aims to enhance T cell responses against intracellular pathogens using silicon-based microchips for improved antigen presentation and novel vaccine development.
Projectdetails
Introduction
Intracellular pathogens and viruses elicit immune responses by presenting their antigens to T cells. At the same time, they have evolved immune evasion mechanisms which essentially reduce the antigenic repertoire that is presented to the immune system.
Project Overview
To overcome this problem, the EIC-funded ICARO project proposes to use silicon-based microchips that carry pathogen antigens and can be internalised by immune cells to aid antigen presentation.
Biochip Advantages
These biochips are retained within cells for a long time and will provide the foundation for a novel vaccination strategy that can boost specific and long-lasting T cell responses.
Consortium Goals
The consortium aims to develop standardized methods for ICARO manufacturing and functionalisation to be easily applicable to different pathogens, thus accelerating the generation of new vaccines in the future.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.997.047 |
| Totale projectbegroting | € 2.997.047 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-3-2026 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ARRAYS-FOR-CELL NANODEVICES SLpenvoerder
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
- INTERUNIVERSITAIR MICRO-ELECTRONICA CENTRUM
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
NanoBiCar: A novel immunotherapy for infectious diseasesNanoBiCar aims to revolutionize bacterial infection treatment through innovative mRNA-based immunotherapy, targeting Mycobacterium tuberculosis to eliminate drug-resistant strains without generating resistance. | EIC Pathfinder | € 2.999.101 | 2025 | Details |
Bottom-up manufacturing of artificial anti-tumor T cellsThe project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment. | EIC Pathfinder | € 3.391.796 | 2024 | Details |
Targeting cancer with mutanome based stem cell vaccineMUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines. | EIC Pathfinder | € 1.782.000 | 2022 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
NanoBiCar: A novel immunotherapy for infectious diseases
NanoBiCar aims to revolutionize bacterial infection treatment through innovative mRNA-based immunotherapy, targeting Mycobacterium tuberculosis to eliminate drug-resistant strains without generating resistance.
Bottom-up manufacturing of artificial anti-tumor T cells
The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.
Targeting cancer with mutanome based stem cell vaccine
MUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
Driving tumour antigen presentation by RNA-mediated transdifferentiationDART aims to develop RNA-mediated reprogramming of tumor cells into antigen-presenting cells to enhance anti-tumor immunity and create a scalable immunotherapy solution. | ERC Proof of... | € 150.000 | 2024 | Details |
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapiesThe TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies. | ERC Advanced... | € 2.500.000 | 2022 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC Proof of... | € 150.000 | 2023 | Details |
RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimmingThe RIPECROP project aims to enhance cancer immunotherapy by developing mRNA-based agents that boost cDC1 cells in tumors to improve anti-tumor T-cell crosspriming. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Driving tumour antigen presentation by RNA-mediated transdifferentiation
DART aims to develop RNA-mediated reprogramming of tumor cells into antigen-presenting cells to enhance anti-tumor immunity and create a scalable immunotherapy solution.
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies
The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming
The RIPECROP project aims to enhance cancer immunotherapy by developing mRNA-based agents that boost cDC1 cells in tumors to improve anti-tumor T-cell crosspriming.